Biotech Patents May Be Easier To Get Under Revised PTO Guidance
This article was originally published in The Gray Sheet
Executive Summary
Yielding to industry pressure, Patent and Trademark Office says both structural and functional changes to what exists in nature should to be considered in assessing patent claims.
You may also be interested in...
Patent Office Guidance Oversteps Myriad Court Decision, Industry Argues
Development of products derived from natural sources will be deterred by PTO’s factor-based approach to patent eligibility, firms contend, noting special concern about examples given in the office’s recent guidance document.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.